التصنيف: antineoplastic المادة الفعالة:polatuzumab
polivy in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) not otherwise specified after at least 2 prior therapies.
